Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1002 for Weight Management in Overweight and Obese Adults
CTR20241151Phase 2Completed
- Sponsor
- Huadong Medicine
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of conveglipron in Overweight, obesity, impaired fasting glucose (IFG), prediabetes, hypertension (HTN), sponsored by Huadong Medicine. Started Apr 2024; status: completed.
02
Drugs
conveglipron
03
Conditions
Overweightobesityimpaired fasting glucose (IFG)prediabeteshypertension (HTN)
Beyond the preview
Go deeper on CTR20241151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241151.